37215壓力測(cè)試儀是經(jīng)典的7200 paw壓力測(cè)試儀的升級(jí)產(chǎn)品自1965年使用以來(lái)該測(cè)試儀在多個(gè)學(xué)術(shù)和工業(yè)實(shí)驗(yàn)室為鎮(zhèn)痛藥物的開(kāi)發(fā)和研究做出了貢獻(xiàn)。

壓痛儀的主要特點(diǎn)

· 提供三種測(cè)試量程250g500g750g

· 簡(jiǎn)單可靠無(wú)需校準(zhǔn)！ 

· 標(biāo)準(zhǔn)為砝碼測(cè)試型號(hào)可根據(jù)需要選擇數(shù)字顯示型號(hào)；

· 提供小鼠專(zhuān)用型號(hào)測(cè)量更準(zhǔn)確；

· 1960年代以來(lái)的經(jīng)典方法發(fā)表論文數(shù)百篇！ 

型號(hào)37215型

· 爪子放置在帶有圓形的錐形推動(dòng)器下方的小底座上；

· 操作人員按下踏板開(kāi)關(guān)壓力由小到大施加到動(dòng)物的爪子上；

· 力以恒定速率增加使得測(cè)試具備很好的可重復(fù)性；

· 動(dòng)物感受到疼痛時(shí)會(huì)產(chǎn)生躲避反應(yīng)；

· 松開(kāi)踏板開(kāi)關(guān)壓力立即停止； 

· 在以10g為步進(jìn)單位施加力；

· 采用低壓同步電機(jī)符合CE規(guī)則；

· 根據(jù)需要可選擇小鼠專(zhuān)用的型號(hào)；

· 數(shù)顯型號(hào)更容易記錄數(shù)據(jù)和讀取數(shù)據(jù)；

· 傳統(tǒng)款式和數(shù)顯款式采用箱體的測(cè)試結(jié)構(gòu)測(cè)量數(shù)據(jù)一致；

· 數(shù)字顯示器采用模塊化設(shè)計(jì)可以對(duì)傳統(tǒng)款式進(jìn)行升級(jí)； 

37215型壓痛儀的主要規(guī)格 
· 電源115或230V50/60Hz

· 功率15W
· 操控方式踏板開(kāi)關(guān)

· 尺寸40 x 16 x 14cm
· 重量2.1Kg

型號(hào)和測(cè)試量程
· 37215大鼠小鼠通用型250g500g750g
· 37216小鼠型號(hào)125g250g375g

壓力模塊

參考文獻(xiàn)

1.Baloh, Robert H et al. “Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALSa phase 1/2a trial." Nature 
medicine vol. 28,9 (2022)1813-1822. doi:10.1038/s41591-022-01956-3
2.Bosse, Gabriel D et al. “The 5α-reductase inhibitor finasteride reduces opioid self-administration in animal models of opioid use disorder." The Journal of clinical 
investigation vol. 131,10 (2021)e143990. doi:10.1172/JCI143990
3.Bang, Sangsu et al. “GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain." The Journal of clinical investigation vol. 128,8 (2018): 
3568-3582. doi:10.1172/JCI99888
4.Goebel, Andreas et al. “Passive transfer of fibromyalgia symptoms from patients to mice." The Journal of clinical investigation vol. 131,13 (2021)e144201. 
doi:10.1172/JCI144201
5.Sikandar, Shafaq et al. “Brain-derived neurotrophic factor derived from sensory neurons plays a critical role in chronic pain." Brain a journal of neurology vol. 141,4 
(2018)1028-1039. doi:10.1093/brain/awy009
6.Vidal-Torres, Alba et al. “Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonismWLB-73502, an analgesic with improved efficacy and 
safety profile compared to strong opioids." Acta pharmaceutica Sinica. B vol. 13,1 (2023)82-99. doi:10.1016/j.apsb.2022.09.018
7.Mousa, Shaaban A et al. “Superior control of inflammatory pain by corticotropin-releasing factor receptor 1 via opioid peptides in distinct pain-relevant brain 
areas." Journal of neuroinflammation vol. 19,1 148. 15 Jun. 2022, doi:10.1186/s12974-022-02498-8
8.Zhou, Danli et al. “Inhibition of apoptosis signal-regulating kinase by paeoniflorin attenuates neuroinflammation and ameliorates neuropathic pain." Journal of 
neuroinflammation vol. 16,1 83. 11 Apr. 2019, doi:10.1186/s12974-019-1476-6
9.Wang, Wenying et al. “Exchange factor directly activated by cAMP-PKCε signalling mediates chronic morphine-induced expression of purine P2X3 receptor in rat 
dorsal root ganglia." British journal of pharmacology vol. 175,10 (2018)1760-1769. doi:10.1111/bph.14191
10.Sala, Emanuele et al. “Improved efficacy, tolerance, safety, and abuse liability profile of the combination of CR4056 and morphine over morphine alone in rodent 
models." British journal of pharmacology vol. 177,14 (2020)3291-3308. doi:10.1111/bph.15049

    3007536621